8-K: Cogent Biosciences: Bezuclastinib NDAs Advance, Strong Cash

Cogent Biosciences announced strong 2025 financial results and significant progress in its bezuclastinib regulatory submissions for multiple indications, including NonAdvSM, GIST, and AdvSM.

Summary

• The SUMMIT NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) was submitted in December 2025.
• The APEX NDA submission for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) is on track for the first half of 2026.
• The PEAK NDA for bezuclastinib in patients with second-line Gastrointestinal Stromal Tumors (GIST) was initiated under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD), with completion on track for April 2026.
• Six abstracts from the SUMMIT trial of bezuclastinib in NonAdvSM patients have been accepted for presentation at the 2026 AAAAI annual meeting.
• The company maintains a strong financial position with $900.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, sufficient to fund operations into 2028.
• Net loss for the full year 2025 was $328.9 million, compared to $255.9 million for the full year 2024.
• Research and development expenses increased to $269.8 million for the year ended December 31, 2025, from $232.7 million for the prior year.
• General and administrative expenses increased to $63.6 million for the year ended December 31, 2025, from $43.3 million for the prior year.
• Inducement equity awards were granted to twelve new employees on February 11, 2026, and February 16, 2026, under the company's 2020 Inducement Plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by significant clinical and regulatory progress for bezuclastinib across multiple indications, coupled with a robust financial position that extends the company's operational runway.

Positives

• SUMMIT NDA for bezuclastinib in NonAdvSM was submitted in December 2025, demonstrating clear clinical benefit across all symptom domains and reduction in objective measures of disease.
• APEX NDA for bezuclastinib in AdvSM is on track for 1H 2026, following topline results showing rapid and deep clinical benefit with an objective response rate of 57% (mIWG) and 80% (PPR), and 89% achieving a 50% reduction in bone marrow mast cells.
• PEAK NDA for bezuclastinib in 2L GIST initiated under FDA's RTOR program and granted Breakthrough Therapy Designation, with completion on track for April 2026.
• The PEAK trial was the first positive Phase 3 trial in second-line GIST patients in over 20 years, showing 16.5 months median progression-free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months for sunitinib monotherapy (HR=0.50, p<0.0001), and a 46% Objective Response Rate (ORR) for the combination versus 26% for monotherapy (p<0.0001).
• Strong financial position with $900.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a cash runway into 2028.
• Successfully completed concurrent public offerings of common stock and convertible senior notes in November 2025, raising net proceeds of approximately $546.8 million.
• Initial preclinical results for CGT1145, a novel JAK2 V617F inhibitor, showcased greater than 100-fold selectivity, positioning it with a potential best-in-class profile.
• Progress on the internally developed KRAS(ON/OFF) inhibitor CGT1263/CGT1815 demonstrated picomolar activity and outcompeted other KRAS exemplars in tumor growth inhibition studies.
• Established active Expanded Access Programs (EAPs) for bezuclastinib in U.S. patients with GIST or SM who meet disease-specific criteria.

Negatives

• Net loss increased to $328.9 million for the full year 2025, compared to $255.9 million for the full year 2024.
• Research and development expenses increased to $269.8 million for the year ended December 31, 2025, from $232.7 million for the prior year, driven by continued development and NDA filings.
• General and administrative expenses increased to $63.6 million for the year ended December 31, 2025, from $43.3 million for the prior year, primarily due to organizational growth and anticipated commercial launch activities.
• Incurred a loss on debt extinguishment of $7.181 million for the year ended December 31, 2025.

Risks

• Forward-looking statements are subject to material risks and uncertainties, including those set forth under the caption Risk Factors in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC.

Future Outlook

The company plans to submit the APEX NDA for bezuclastinib in AdvSM in the first half of 2026 and complete the PEAK NDA submission for GIST in April 2026. FDA acceptance of the NonAdvSM NDA is expected in February 2026. Pending FDA approval, bezuclastinib is targeted for launch in the second half of 2026. The company also plans to submit Investigational New Drug (IND) applications for CGT1815 and CGT1145, and present clinical data for CGT4859, CGT4255, and CGT6297. The current cash position is sufficient to fund operations into 2028.

Management Comments

• "Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway." Andrew Robbins, President and Chief Executive Officer.
• "We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDAs RTOR program for bezuclastinib in patients with second-line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year." Andrew Robbins, President and Chief Executive Officer.
• "These recent and upcoming milestones underscore the breadth of bezuclastinibs best-in-class potential across KIT-mutant driven diseases." Andrew Robbins, President and Chief Executive Officer.
• "With a very strong balance sheet entering 2026, we will soon finish building our commercial organization and will be ready to launch bezuclastinib in the second half of 2026." Andrew Robbins, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Cogent Biosciences is making significant strides in the precision oncology and rare disease space, particularly with its lead candidate bezuclastinib targeting KIT-mutant driven diseases like Systemic Mastocytosis and GIST. The successful Phase 3 trials and multiple NDA submissions position the company as a potential leader in these niche but high-value markets, competing with other targeted therapy developers. The focus on "best-in-class potential" for bezuclastinib and other pipeline candidates like JAK2 V617F and KRAS inhibitors indicates a strategy to address genetically defined diseases with highly selective therapies, aligning with broader industry trends towards personalized medicine.

Comparison to Industry Standards

• The PEAK trial's 16.5 months median progression-free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months for sunitinib monotherapy (HR=0.50, p<0.0001) represents the first positive Phase 3 trial in second-line GIST patients in over 20 years, setting a new benchmark in this specific treatment area.
• The objective response rate (ORR) of 46% for the bezuclastinib combination versus 26% for sunitinib monotherapy in 2L GIST also demonstrates a significant improvement over existing standards.
• The preclinical results for CGT1145 showing greater than 100-fold selectivity for JAK2 V617F mutations over JAK2 WT inhibition suggest a potentially superior safety and efficacy profile compared to less selective JAK2 inhibitors in development or on the market for myeloproliferative neoplasms.
• The outcompete data for CGT1263/CGT1815 against other KRAS exemplars, including RMC-6236, in tumor growth inhibition studies indicates a competitive profile in the rapidly evolving KRAS inhibitor landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical and regulatory progress, extended cash runway, and potential for future product launches and revenue growth.
• Patients (NonAdvSM, AdvSM, GIST): Positive impact due to the advancement of bezuclastinib towards market approval, offering new treatment options, and the availability of Expanded Access Programs.
• Employees: Positive impact due to continued organizational growth, hiring of new employees, and equity awards designed to incentivize performance.
• Creditors: Positive impact due to a strong cash position and the repayment of $54.8 million in long-term debt, enhancing financial stability.

Next Steps

• Acceptance of the NDA for bezuclastinib in NonAdvSM in February 2026.
• Complete submission of PEAK NDA in April 2026 for bezuclastinib in patients with GIST who have received prior treatment with imatinib.
• Submit APEX NDA in 1H 2026 for bezuclastinib in patients with AdvSM.
• Present detailed clinical data from the PEAK and APEX pivotal trials at major medical meetings during 1H 2026.
• Present updated SUMMIT data across six poster presentations at the AAAAI Annual meeting in February 2026.
• Pending FDA approval, launch bezuclastinib in the second half of 2026.
• Submit Investigational New Drug (IND) applications for CGT1815, Cogent's novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent's novel, selective JAK2 V617F inhibitor.
• Share clinical data on CGT4859, Cogent's selective and potent FGFR 2/3 inhibitor, from its Phase 1/2 study in patients with alterations in FGFR2 or FGFR3.
• Complete dose escalation for both CGT4255, Cogent's CNS-penetrant, selective mutant ErbB2 inhibitor, and CGT6297, Cogent's novel, selective PI3Ka inhibitor.
• Attend the Leerink Healthcare Conference on Wednesday, March 11, 2026.

Key Dates

Recommendation

The company has demonstrated exceptional progress with its lead asset, bezuclastinib, securing positive pivotal trial results across three indications and advancing multiple NDA submissions, including one under Breakthrough Therapy Designation and Real-Time Oncology Review. The robust cash position, extended runway into 2028, and clear path to commercialization in late 2026 significantly de-risk the investment. The strong pipeline beyond bezuclastinib further adds long-term value. These factors collectively indicate a compelling investment opportunity for substantial future growth.

Keywords

bezuclastinib, Systemic Mastocytosis, Gastrointestinal Stromal Tumors, NonAdvSM, AdvSM, GIST, KIT D816V, tyrosine kinase inhibitor, oncology, biotechnology, clinical trials, NDA, FDA, RTOR, BTD, CGT1145, JAK2 V617F, CGT1263, KRAS, CGT1815, FGFR2, ErbB2, PI3Ka